Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving irradiated donor lymphocytes together with rituximab may kill more cancer cells.
PURPOSE: This clinical trial is studying the side effects and how well giving irradiated donor lymphocytes together with rituximab works in treating patients with relapsed or refractory lymphoproliferative disease.
Full description
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a pilot study.
Peripheral blood is collected periodically during study for correlative laboratory studies. Blood samples are analyzed for FcγIIIA polymorphism by fluorescent in situ hybridization or by reverse transcriptase-polymerase chain reaction. Survival of donor lymphocytes is assessed by chimerism studies.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
DISEASE CHARACTERISTICS:
Histologically confirmed lymphoproliferative disease
Bidimensionally measurable disease OR abnormal cells detected in blood
Resistant or refractory to standard therapies and/or unlikely to benefit from additional standard therapies* AND meets 1 of the following criteria:
Disease with anticipated response rate < 20% after treatment with rituximab alone, including any of the following:
Relapsed or progressive disease after prior treatment with rituximab, including any of the following:
Hodgkin's lymphoma
Hairy cell leukemia
Chronic lymphocytic leukemia/small lymphocytic lymphoma meeting any of the following criteria:
B-cell prolymphocytic leukemia meeting any of the following criteria:
Lymphoplasmacytic lymphoma, marginal zone lymphoma, mucosa-associated lymphoid tissue lymphoma, or follicular lymphoma meeting any of the following criteria:
Multiple myeloma meeting any of the following criteria:
Mantle cell lymphoma meeting the following criteria:
Diffuse large B-cell lymphoma meeting any of the following criteria:
Burkitt's lymphoma meeting any of the following criteria:
Lymphomatoid granulomatosis meeting any of the following criteria:
Acute lymphocytic leukemia meeting any of the following criteria:
No active CNS malignancy
Not considered a candidate for allogeneic HSCT
HLA-partially matched (≥ 2/6) related donor available
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Primary purpose
Allocation
Interventional model
Masking
2 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal